Contract Biomanufacturing Global Market -Forecast to 2027

Publishing Date : December, 2018
Report Code : HCPH0111
Price:
Single license $4,950
Site license $6,750
Global license $9,000


 

Biomanufacturing is a widely used term to describe the manufacture of biologic molecules for various stages of drug development right from pre-clinical stage to commercial supply. The biologic drug manufacturing is a complex process involving huge capital and sound technical expertise. Many large and small pharmaceutical companies are turning to outsource the drug manufacture process to reduce capital investments on capacities and focus more on their core competencies. Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacture, more efficient and often less costly. In addition to that, the use of single-use bioreactors is effectively reducing the manufacture facility cost. This option is more viable for smaller and low-funded companies for their in-house candidate product manufacturing needs, whereby, the companies can avoid $50-$150 million facility costs for construction of fixed, dedicated stainless steel bioreactor-based bioprocessing systems and outsource their manufacturing requirements to CMOs which use single-use facilities which typically cost $25-$40 million for commercial manufacture.

There is a continued growth of the biopharmaceutical market which is expected to nearly double in the next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include less-developed countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets. Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals. Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar (and bio-betters) companies to enter into the world’s biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture. Hence, there is every reason to assume that future growth in biopharmaceutical outsourcing will continue at a minimum of 14% in western countries to about 18% in Asian countries.

Nowadays CMOs are gaining much prominence due to increased demand for the clinical and commercial supply of biologics. Such prominence is achieved mainly through capacity expansions or more easily through mergers and acquisitions. In October 2018, Boehringer Ingelheim, is one of the worlds’ largest manufactures of biopharmaceutical, completed the expansion of biopharmaceutical facility by increasing capacity of bioreactor to 290,000L, now company is  well positioned to manufacture future biopharmaceutical medicines, both from its own research pipeline and as contract manufacturer for other pharmaceutical and biopharmaceutical companies. Contract manufacturing services are mainly benefitting the small-scale companies, which lack the facilities for the bio-manufacturing and also intend to not invest in fixed assets like steel bioreactors and bioprocessing facilities thus giving an opportunity for the CMOs to gain market presence.

The contract biomanufacturing global market is dominated by North American region commanded the largest revenue in 2018 and expected to grow at a double digit CAGR according to IQ4I estimation. The Asia Pacific region is witnessing huge growth opportunities in terms of biologics outsourcing and many local contract manufacturing organizations are taking the lead in making this region the most sought after destination for biologics outsourcing. Some of the reasons why countries such as China and India are favourite destinations for such projects include the lower cost of labour, higher technical expertise and favourable government regulations in countries such as China. The Asia-Pacific is expected to grow at highest double digit CAGR from 2018 to 2027.

The global bio-manufacturing outsourcing market is driven by factors such as globalization of bio-manufacturing facilities, increased funding from private venture capitals and government organizations, increasing outsourcing budgets and the emergence of latest technologies such as single-use bioreactors. An example of such investment includes WuXi Biologics, a contract development and manufacturing organization invested $240 million in a 25-acre site which is located in Shijiazhuang for the development of labs, as well as clinical manufacturing capabilities with a 5,000L bioreactor and 48,000L bioreactor for commercial manufacturing. There are restraints and threats as well which could potentially hamper the biomanufacturing outsourcing market. These include unequal distribution of biomanufacturing capacities around the globe which could pose capacity constraints in future, Stringent regulatory affairs and mandatory cGMP certifications which could make the drug manufacture process to further low down, outsourcing being restricted to only small and mid-sized companies are another major restraint where large companies are looking for CMOs as an option only when there are insufficient capabilities internally.

  • 1     CONTRACT BIOMANUFACTURING GLOBAL MARKET
    • 1.1     EXECUTIVE SUMMARY
  • 2     MARKET ANALYSIS
    • 2.1     FACTORS INFLUENCING MARKET
      • 2.1.1     DRIVERS AND OPPORTUNITIES
        • 2.1.1.1     GLOBALIZATION OF OUTSOURCING FOR BIO-MANUFACTURING
        • 2.1.1.2     INCREASED FUNDING FROM PRIVATE INVESTORS AND GOVERNMENT FOR DEVELOPMENT OF CMOS
        • 2.1.1.3     THE EMERGENCE OF SINGLE-USE BIOREACTORS
        • 2.1.1.4     INCREASING BIOLOGICS APPROVALS IN THE PAST YEAR
        • 2.1.1.5     SUCCESSFUL COLLABORATION AND LOW COST FOR OUTSOURCING
      • 2.1.2     RESTRAINTS AND THREATS
        • 2.1.2.1     THE HIGH REQUIREMENT FOR CAPITAL INVESTMENTS RESTRAINING MANY CMOS TO ENTER THE BIOLOGICS SPACE
        • 2.1.2.2     RISK OF PRODUCT CONTAMINATION & MAINTAINING HIGH PRODUCTIVITY
        • 2.1.2.3     ENTRY OF LARGE PHARMACEUTICAL COMPANY WITH EXCESS CAPACITY INTO THE CMO MARKET
        • 2.1.2.4     STRINGENT REGULATIONS AND MANDATORY REQUIREMENT OF CGMP CERTIFICATIONS
  • 3     CONTRACT BIOMANUFACTURING SERVICES
    • 3.1     INTRODUCTION
    • 3.2     CONTRACT BIOMANUFACTURING, BY PROCESS
      • 3.2.1     BIOMANUFACTURING BY MAMMALIAN CELL CULTURE
      • 3.2.2     BIOMANUFACTURING BY MICROBIAL CELL CULTURE
      • 3.2.3     BIOMANUFACTURING BY OTHER CELL CULTURE
    • 3.3     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY END USERS
      • 3.3.1     CONTRACT BIOMANUFACTURING OF DIAGNOSTICS
      • 3.3.2     CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS
      • 3.3.3     CONTRACT BIOMANUFACTURING OF THERAPEUTICS
    • 3.4     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY REGION
    • 3.5     COMPETITIVE LANDSCAPE
      • 3.5.1     CAPACITY COMPARISON
      • 3.5.2     CONTRACT BIOMANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS
    • 3.6     COMPANY DEVELOPMENTS
      • 3.6.1     MERGER AND ACQUISITION BY CMOS
      • 3.6.2     COLLABORATIONS
      • 3.6.3     CAPACITY EXPANSIONS
  • 4     COMPANY PROFILES
    • 4.1     ABZENA PLC
      • 4.1.1     OVERVIEW
      • 4.1.2     FINANCIALS
      • 4.1.3     SERVICE PORTFOLIO
      • 4.1.4     KEY DEVELOPMENTS
      • 4.1.5     SWOT ANALYSIS
    • 4.2     ALBANY MOLECULAR RESEARCH INC
      • 4.2.1     OVERVIEW
      • 4.2.2     FINANCIALS
      • 4.2.3     SERVICE PORTFOLIO
      • 4.2.4     KEY DEVELOPMENTS
      • 4.2.5     SWOT ANALYSIS
    • 4.3     ASAHI GLASS CO. LTD. (AGC BIOSCIENCE/CMC BIOLOGICS)
      • 4.3.1     OVERVIEW
      • 4.3.2     FINANCIALS
      • 4.3.3     SERVICE PORTFOLIO
      • 4.3.4     KEY DEVELOPMENTS
      • 4.3.5     SWOT ANALYSIS
    • 4.4     BOEHRINGER INGELHEIM
      • 4.4.1     OVERVIEW
      • 4.4.2     FINANCIALS
      • 4.4.3     SERVICE PORTFOLIO
      • 4.4.4     KEY DEVELOPMENTS
      • 4.4.5     SWOT ANALYSIS
    • 4.5     CATALENT INC.
      • 4.5.1     OVERVIEW
      • 4.5.2     FINANCIALS
      • 4.5.3     SERVICE PORTFOLIO
      • 4.5.4     KEY DEVELOPMENTS
      • 4.5.5     SWOT ANALYSIS
    • 4.6     CHARLES RIVER LABORATORIES
      • 4.6.1     OVERVIEW
      • 4.6.2     FINANCIALS
      • 4.6.3     SERVICE PORTFOLIO
      • 4.6.4     KEY DEVELOPMENTS
      • 4.6.5     SWOT ANALYSIS
    • 4.7     FUJIFILM DIOSYNTH BIOTECHNOLOGIES (FUJIFILM HOLDINGS CORPORATION)
      • 4.7.1     OVERVIEW
      • 4.7.2     FINANCIALS
      • 4.7.3     SERVICE PORTFOLIO
      • 4.7.4     KEY DEVELOPMENTS
      • 4.7.5     SWOT ANALYSIS
    • 4.8     HORIZON DISCOVERY GROUP, PLC
      • 4.8.1     OVERVIEW
      • 4.8.2     FINANCIALS
      • 4.8.3     SERVICE PORTFOLIO
      • 4.8.4     KEY DEVELOPMENTS
      • 4.8.5     SWOT ANALYSIS
    • 4.9     JHL BIOTECH INC.
      • 4.9.1     OVERVIEW
      • 4.9.2     FINANCIALS
      • 4.9.3     SERVICE PORTFOLIO
      • 4.9.4     KEY DEVELOPMENTS
      • 4.9.5     SWOT ANALYSIS
    • 4.10     LONZA GROUP
      • 4.10.1     OVERVIEW
      • 4.10.2     FINANCIALS
      • 4.10.3     SERVICE PORTFOLIO
      • 4.10.4     KEY DEVELOPMENTS
      • 4.10.5     SWOT ANALYSIS
    • 4.11     MERCK KGAA
      • 4.11.1     OVERVIEW
      • 4.11.2     FINANCIALS
      • 4.11.3     PRODUCT PORTFOLIO
      • 4.11.4     KEY DEVELOPMENTS
      • 4.11.5     SWOT ANALYSIS
    • 4.12     PROTEOGENIX
      • 4.12.1     OVERVIEW
      • 4.12.2     FINANCIALS
      • 4.12.3     SERVICE PORTFOLIO
      • 4.12.4     KEY DEVELOPMENTS
      • 4.12.5     SWOT ANALYSIS
    • 4.13     RENTSCHLER BIOTECHNOLOGIE GMBH
      • 4.13.1     OVERVIEW
      • 4.13.2     FINANCIALS
      • 4.13.3     SERVICE PORTFOLIO
      • 4.13.4     KEY DEVELOPMENTS
      • 4.13.5     SWOT ANALYSIS
    • 4.14     SAMSUNG BIOLOGICS
      • 4.14.1     OVERVIEW
      • 4.14.2     FINANCIALS
      • 4.14.3     SERVICE PORTFOLIO
      • 4.14.4     KEY DEVELOPMENTS
      • 4.14.5     SWOT ANALYSIS
    • 4.15     JSR LIFE SCIENCES (SELEXIS SA)
      • 4.15.1     OVERVIEW
      • 4.15.2     FINANCIALS
      • 4.15.3     SERVICE PORTFOLIO
      • 4.15.4     KEY DEVELOPMENTS
      • 4.15.5     SWOT ANALYSIS
    • 4.16     SYNGENE INTERNATIONAL
      • 4.16.1     OVERVIEW
      • 4.16.2     FINANCIALS
      • 4.16.3     SERVICE PORTFOLIO
      • 4.16.4     KEY DEVELOPMENTS
      • 4.16.5     SWOT ANALYSIS
    • 4.17     PATHEON N.V. (THERMO FISHER SCIENTIFIC)
      • 4.17.1     OVERVIEW
      • 4.17.2     FINANCIALS
      • 4.17.3     SERVICE PORTFOLIO
      • 4.17.4     KEY DEVELOPMENTS
      • 4.17.5     SWOT ANALYSIS
    • 4.18     WUXI BIOLOGICS (WUXI APPTEC)
      • 4.18.1     OVERVIEW
      • 4.18.2     FINANCIALS
      • 4.18.3     SERVICE PORTFOLIO
      • 4.18.4     KEY DEVELOPMENTS
      • 4.18.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CAPACITY COMPARISON OF CONTRACT MANUFACTURING ORGANIZATIONS V’S IN-HOUSE CAPACITIES (L)
      • TABLE 2     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY STAGE ($BN)
      • TABLE 3     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY PROCESS ($BN)
      • TABLE 4     CONTRACT MANUFACTURING ORGANIZATIONS CAPACITY, BY PROCESS (L)
      • TABLE 5     DRUGS SYNTHESIZED IN MICROBIAL CELL CULTURE
      • TABLE 6     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS 2017-2027 ($BN)
      • TABLE 7     SELECTED FDA APPROVED THERAPEUTIC PEPTIDES AND PROTEINS
      • TABLE 8     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BY REGION 2017-2027 ($BN)
      • TABLE 9     COMPANY COMPARISON MATRIX, BY MANUFACTURING CAPABILITY
      • TABLE 10     MERGERS AND ACQUISITIONS (2017-2018)
      • TABLE 11     COLLABORATIONS (2017-2018)
      • TABLE 12     CAPACITY EXPANSIONS (2017-2018)
      • TABLE 13     ABZENA PLC: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 14     ABZENA PLC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 15     ABZENA PLC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 16     ASAHI GLASS CO. LTD.: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(Q3)) ($MN)
      • TABLE 17     ASAHI GLASS CO. LTD. : TOTAL REVENUE, BY SEGMENTS, (2016-2018(Q3)) ($MN)
      • TABLE 18     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 19     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 20     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 21     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 22     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 23     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(Q3)) ($MN)
      • TABLE 24     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2016-2018(Q3)) ($MN)(2016-2018(Q3)) ($MN)
      • TABLE 25     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(Q3)) ($MN)
      • TABLE 26     FUJIFILM DIOSYNTH (FUJIFILM HOLDINGS CORPORATION): TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)
      • TABLE 27     FUJIFILM DIOSYNTH (FUJIFILM HOLDINGS CORPORATION): TOTAL REVENUE, BY SEGMENTS (2016-2018(H1)) ($MN)
      • TABLE 28     FUJIFILM DIOSYNTH (FUJIFILM HOLDINGS CORPORATION): TOTAL REVENUE, BY GEOGRAPHY (2017-2019(H1)) ($MN)
      • TABLE 29     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)
      • TABLE 30     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2016-2018(H1)) ($MN)
      • TABLE 31     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(H1)) ($MN)
      • TABLE 32     JHL BIOTECH: TOTAL REVENUE AND R & D EXPENSES (2015-2017) ($MN)
      • TABLE 33     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES (2016-2018(H1)) ($MN)
      • TABLE 34     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2016-2018(H1)) ($MN)
      • TABLE 35     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2016-2018(H1)) ($MN)
      • TABLE 36     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)
      • TABLE 37     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2016-2018(H1)) ($MN)
      • TABLE 38     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(H1)) ($MN)
      • TABLE 39     SAMSUNG BIOLOGICS CO., LTD: TOTAL REVENUE AND R&D EXPENSES (2016-2018(H1) ($MN)
      • TABLE 40     SAMSUNG BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY (2016-2018(H1)) ($MN)
      • TABLE 41     SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)
      • TABLE 42     SYNGENE INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(H1)) ($MN)
      • TABLE 43     PATHEON (THERMO FISHER SCIENTIFIC): TOTAL REVENUE AND R&D EXPENSES (2016-2018(Q3)) ($MN)
      • TABLE 44     PATHEON(THERMO FISHER SCIENTIFIC): TOTAL REVENUE, BY SEGMENT, (2016-2018(Q3)) ($MN)
      • TABLE 45     WUXI BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MARKET DYNAMICS
      • FIGURE 2     GLOBAL MANUFACTURING CAPACITY, CGMP V’S NON-CGMP, INHOUSE V’S CMO, 2017-2027
      • FIGURE 3     CAPACITY UTILIZATION OF CONTRACT MANUFACTURING ORGANIZATIONS, BY STAGE (L)
      • FIGURE 4     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY STAGE ($BN)
      • FIGURE 5     CONTRACT BIOMANUFACTURING GLOBAL MARKET REVENUE, BY PROCESS ($BN)
      • FIGURE 6     CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (L)
      • FIGURE 7     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS ($BN)
      • FIGURE 8     ADC PIPELINE FOR CANCER 2018
      • FIGURE 9     OUTLOOK OF BIOLOGICS CMO GLOBAL MARKET, BY REGION (%) AND MANUFACTURING IN METRIC TONS, 2018
      • FIGURE 10     CAPACITY COMPOSITION OF TOP 10 CONTRACT MANUFACTURING ORGANIZATIONS (L)
      • FIGURE 11     MARKET SHARE ANALYSIS BY CONTRACT BIOMANUFACTURING MAJOR PLAYERS, 2018
      • FIGURE 12     COMPANY DEVELOPMENTS (2017-2018)
      • FIGURE 13     OVERVIEW: ABZENA PLC
      • FIGURE 14     SWOT: ABZENA PLC
      • FIGURE 15     SWOT: ALBANY MOLECULAR RESEARCH, INC
      • FIGURE 16     OVERVIEW: ASAHI GLASS CO. LTD.
      • FIGURE 17     SWOT: ASAHI GLASS CO. LTD.
      • FIGURE 18     OVERVIEW: BOEHRINGER INGELHEIM
      • FIGURE 19     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 20     OVERVIEW: CATALENT INC.
      • FIGURE 21     SWOT: CATALENT INC.
      • FIGURE 22     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 23     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 24     OVERVIEW: FUJIFILM HOLDINGS CORPORATION
      • FIGURE 25     SWOT: FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • FIGURE 26     OVERVIEW: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 27     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 28     OVERVIEW: JHL BIOTECH INC.
      • FIGURE 29     SWOT: JHL BIOTECH INC.
      • FIGURE 30     OVERVIEW: LONZA GROUP
      • FIGURE 31     SWOT: LONZA GROUP
      • FIGURE 32     OVERVIEW: MERCK KGAA
      • FIGURE 33     SWOT: MERCK KGAA
      • FIGURE 34     SWOT: PROTEOGENIX
      • FIGURE 35     SWOT: RENTSCHLER BIOTECHNOLOGIES
      • FIGURE 36     OVERVIEW: SAMSUNG BIOLOGICS
      • FIGURE 37     SWOT: SAMSUNG BIOLOGICS
      • FIGURE 38     SWOT: JSR LIFE SCIENCES (SELEXIS SA)
      • FIGURE 39     OVERVIEW: SYNGENE INTERNATIONAL
      • FIGURE 40     SWOT: SYNGENE INTERNATIONAL
      • FIGURE 41     OVERVIEW: PATHEON (THERMO FISHER SCIENTIFIC)
      • FIGURE 42     SWOT: PATHEON (THERMO FISHER SCIENTIFIC)
      • FIGURE 43     OVERVIEW: WUXI BIOLOGICS (WUXI APPTEC)
      • FIGURE 44     SWOT: WUXI BIOLOGICS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABBVIE CONTRACT MANUFACTURING
      • 2     ABNOVA
      • 3     ABZENA
      • 4     AFFINITY LIFESCIENCES
      • 5     AJINOMOTO ALTHEA, INC.
      • 6     ALEXION PHARMACEUTICALS
      • 7     AMRI
      • 8     ANOGEN
      • 9     AGC ASAHI GLASS (CMC BIOLOGICS)
      • 10     AVID BIOSERVICES
      • 11     BHARAT BIOTECH LTD
      • 12     BINEX CO. LTD.
      • 13     BIOCONNECT LIFE SCIENCES
      • 14     BIODEXTRIS
      • 15     BIOGEN
      • 16     BIORELIANCE SAFC
      • 17     BOEHRINGER INGELHEIM
      • 18     CADILA HEALTHCARE LTD
      • 19     CATALENT INC.
      • 20     CELLTRION
      • 21     CEVEC PHARMACEUTICALS GMBH
      • 22     CHARLES RIVER LABORATORIES
      • 23     COBRA BIOLOGICS
      • 24     COVANCE RESEARCH PRODUCTS
      • 25     CYTOVANCE BIOLOGICS
      • 26     DENDREON CORPORATION
      • 27     DIATHEVA
      • 28     ENVIGO
      • 29     EUROPA BIOPRODUCTS
      • 30     EUROFINS
      • 31     EVOTEC
      • 32     FAPON
      • 33     FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • 34     GTP TECHNOLOGY
      • 35     HORIZON DISCOVERY
      • 36     IMMUNOREAGENTS
      • 37     INNO BIOLOGICS
      • 38     INNOVENT BIO
      • 39     INTAS PHARMACEUTICALS
      • 40     JHL BIOTECH
      • 41     JSR CORPORATION (KBI BIOPHARMA)
      • 42     JUBILANT HOLLISTER-STIER
      • 43     KEMWELL BIOPHARMA
      • 44     LAKE PHARMA
      • 45     LAMPIRE BIOLOGICAL LABORATORIES
      • 46     LONZA
      • 47     LUINA BIO
      • 48     MENARINI BIOTECH S.R.L
      • 49     MERCK GMBH
      • 50     MILTENYI BIOTECH GMBH
      • 51     NOVASEP
      • 52     OMNIA BIOLOGICS
      • 53     PARAGON BIOSERVICES
      • 54     PATHEON
      • 55     PREMAS BIOTECH PVT LTD
      • 56     PROTEOGENIX
      • 57     RENTSCHLER BIOTECHNOLOGIE
      • 58     SAMSUNG BIOLOGICS
      • 59     SANDOZ GMBH
      • 60     SCRIPPS LABORATORIES
      • 61     SELEXIS S.A.
      • 62     SERUM INSTITUTE OF INDIA
      • 63     SYNGENE
      • 64     THERAPURE BIOPHARMA
      • 65     TOYOBO CO. LTD.
      • 66     U-PROTEIN EXPRESS BV
      • 67     VIFOR PHARMA LTD
      • 68     WAISMAN CLINICAL BIOMANUFACTURING
      • 69     WUXI BIOLOGICS (WUXI APPTEC)
      • 70     XCELLEREX
      • 71     ZYMEWORKS INC.